摘要
目的:观察米曲菌胰酶片联合雷贝拉唑和莫沙必利治疗反流性食管炎(RE)伴功能性消化不良(FD)患者的效果。方法:选取2020年3月至2022年3月该院收治的88例RE伴FD患者进行前瞻性研究,按照随机数字表法将其分为观察组与对照组各44例。对照组给予雷贝拉唑钠肠溶片联合枸橼酸莫沙必利片治疗,观察组在对照组基础上给予米曲菌胰酶片治疗,比较两组疗效、症状评分、胃肠动力学指标[上食管括约肌压力(UESP)、下食管括约肌压力(LESP)、促胃动素(MTL)]水平和酸反流指标(酸暴露时间、酸反流次数)水平。结果:观察组治疗总有效率为95.45%,明显高于对照组的77.27%,差异有统计学意义(P<0.05);治疗后,两组反酸、胸骨后疼痛症状评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组UESP、LESP和MTL水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);治疗后,两组酸暴露时间均短于治疗前,且观察组短于对照组,两组酸反流次数均少于治疗前,且观察组少于对照组,差异有统计学意义(P<0.05)。结论:米曲菌胰酶片联合雷贝拉唑和莫沙必利治疗RE伴FD患者可提高治疗总有效率和胃肠动力学指标水平,降低症状评分,缩短酸暴露时间,以及减少酸反流次数,效果优于雷贝拉唑联合莫沙必利治疗。
Objective:To observe effects of triple therapy of Oryz-aspergillus enzyme and pancreatin tablets,Rabeprazole and Mosapride on patients with reflux esophagitis(RE)and functional dyspepsia(FD).Methods:A prospective study was conducted on 88 patients with RE and FD admitted to the hospital from March 2020 to March 2022.According to the random number table method,they were divided into observation group and control group,44 cases in each.The control group was treated with Rabeprazole sodium enteric-coated tablets combined with Mosapride citrate tablets,while the observation group was treated with Oryz-aspergillus enzyme and pancreatin tablets on the basis of that of the control group.The efficacy,the symptom score,the gastrointestinal motility index levels[upper esophageal sphincter pressure(UESP),lower esophageal sphincter pressure(LESP),motilin(MTL)],and the acid reflux index levels(acid exposure time,acid reflux time)were compared between the two groups.Results:The total effective rate of treatment in the observation group was 95.45%,which was significantly higher than 77.27%in the control group,and the difference was statistically significant(P<0.05).After the treatment,the symptom scores of the two groups were lower than those before the treatment,that in the observation group was lower than that in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of UESP,LESP and MTL in the two groups were higher than those before the treatment,those in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).Further,after the treatment,the acid exposure time of the two groups was shorter than that before treatment,and that in the observation group was shorter than that in the control group;the acid reflux times in the two groups was less than that those before the treatment,and that in the observation group was less than that in the control group;and the difference was statistically significant(P<0.05).Conclusions:Oryz-aspergillus enzyme and pancreatin tablets combined with Rabeprazole and Mosapride in the treatment of the patients with RE and FD can improve the total effective rate and the gastrointestinal motility index levels,reduce the symptom scores,shorten the acid exposure time,and reduce the acid reflux time.Moreover,it is superior to Rabeprazole combined with Mosapride treatment.
作者
殷晓飞
罗文霞
YIN Xiaofei;LUO Wenxia(Yangxin County People’s Hospital,Huangshi 435200 Hubei,China)
出处
《中国民康医学》
2023年第11期81-83,共3页
Medical Journal of Chinese People’s Health
关键词
反流性食管炎
功能性消化不良
雷贝拉唑
莫沙必利
米曲菌胰酶
胃肠动力学
症状
Reflux esophagitis
Functional dyspepsia
Rabeprazole
Mosapride
Oryz-aspergillus enzyme and pancreatin
Gastrointestinal dynamics
Symptom
